Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylvania.
The science-driven company said the logistical initiative further strengthens its commitment to scientific discovery and growth potential.
“This move reinforces the company’s commitment to growth, solidifying its footprint and expanding the laboratory and center for artificial intelligence in Pittsburgh,” Predictive Oncology CEO Raymond Vennare said in a statement.
“Our company not only employs some of the world’s leading scientists in their respective fields, but has access to a critical mass of talent, many of whom were drawn to the region by Carnegie Mellon University, the University of Pittsburgh and UPMC Medical Center,” he added.
Predictive Oncology noted that the move follows the company’s recent expansion to nearly 20,000 feet of prime commercial space in the Lawrenceville section of Pittsburgh, a city known for its world-renowned universities and medical centers.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Contact Sean at sean@proactiveinvestors.com